BILL ANALYSIS

HR10024

BEARISH

To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require health insurance issuers and MA organizations to make publicly available certain information with respect to coverage request rejection.

HR10024 (To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require health insurance issuers and MA organizations to make publicly available certain information with respect to coverage request rejection.) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR10024 is a low-impact transparency bill that imposes compliance costs on health insurers but no direct funding.

Medicare Advantage-focused insurers like UNH and HUM are most exposed to the disclosure requirement.

The bill is in early stage with no cosponsors, making passage unlikely in the current session.

How HR10024 Affects the Market

The bill's introduction is unlikely to move stock prices materially. For $UNH, with $371.6B revenue, incremental compliance costs are trivial. For $HUM, which is more concentrated in MA, the impact is relatively larger but still not transformative. Any sell-off would be shallow and short-lived. Investors should monitor whether the bill gains committee traction or cosponsors—if it does, the regulatory risk to MA insurers could rise, but current odds are low.

Bill Details

Metric	Value
Bill Number	HR10024
Market Sentiment	bearish
Event Date	August 3, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR10024, introduced in the House and referred to Energy and Commerce and Ways and Means, would require health insurers and Medicare Advantage organizations to publicly disclose coverage request rejection information. This early-stage transparency bill imposes compliance costs and reputational risk on major insurers like UNH, HUM, CVS, and CI, but has no direct funding or immediate revenue impact. The market impact is limited to administrative burden and potential public scrutiny of denial rates.

Full AI Market Analysis

1) What happened: On August 3, 2026, Rep. Hinson (R-IA) introduced HR10024, which amends the Public Health Service Act and Social Security Act to require health insurance issuers and Medicare Advantage organizations to make publicly available information about coverage request rejections. The bill was referred to the Energy and Commerce and Ways and Means committees. It is at the earliest legislative stage with no cosponsors and no committee action yet. 2) The money trail: This bill authorizes no funding. It is a regulatory mandate on private insurers, not a spending program. The cost to insurers is administrative—implementing systems to compile and publish rejection data. There is no appropriation involved, so the federal government spends nothing directly. The financial impact is a compliance cost on affected companies, which is likely to be modest relative to their revenue bases. 3) Convergence: No related signals or procurement data were provided. This is an isolated transparency bill. However, it aligns with a broader regulatory trend of increasing healthcare pricing and coverage transparency, though no specific White House action or companion bill is present. The absence of convergence means the bill should be analyzed on its own merits. 4) Structural winners and losers: The clear losers are Medicare Advantage insurers that will face new disclosure requirements. UNH, HUM, CVS (Aetna), and CI are the public pure-plays or major players in this space. The bill does not create any winners—consumers may benefit from transparency, but no public company is directly advantaged. The impact is a mild negative administrative burden and potential reputational risk. 5) Timeline: The bill is in early stages. It will need committee hearings, markup, and a floor vote in the House, then Senate passage and presidential action. Given the 119th Congress is halfway through (2026), the probability of enactment in this session is low. Most similar transparency bills stall. If it does pass, implementation would occur after a rulemaking period, likely 1-2 years after enactment.